The atherogenic impact and functional capacity of LCAT was studied and discussed over a half century. This review aims to clarify the key points that may affect the final decision on whether LCAT is an anti-atherogenic or atherogenic factor. There 
Introduction
The butterfly effect expresses the sensitive dependence of the development of a system on initial conditions whose small changes can result in large variations... WIKIPEDIA Lecithin cholesterol acyltransferase (LCAT, EC 2.3.1.43) is a plasma enzyme which catalyzes the transfer of fatty acids from 2n-lecithin to 3-hydroxy group of free cholesterol (FC) to form cholesteryl esters (CE) and lysolecithin (LPC). LCAT as the producer of a majority of cholesteryl esters in the human plasma has a unique role in the removal of unesterified cholesterol from peripheral cells, including macrophages into plasma lipoproteins in the pathway of reverse cholesterol transport (RCT) (Glomset et al. 1966 , Glomset 1968 . This was the basis for considering its role in the atherogenic process. There was a long-term attempt for finding the evidence that would support the manipulation of LCAT in the treatment of diseases of atherogenic Vol. 66 origin. Even more than 50 years of monitoring on proand anti-atherogenic LCAT impact did not provide a reliable answer. Since 1962, when the LCAT mechanism was first described (Glomset 1962) , Google has monitored about 660 000 records of LCAT. Among them 86 000 records followed the relationship between LCAT and atherosclerosis or cardiovascular diseases (CVD). During this time thousands of details have been discovered that complement the pathway of FC from peripheral tissues to the intravascular pool, being transformed by the action of LCAT into cholesteryl esters which leave the pool. However, further knowledge about the characteristics and modus operandi of LCAT, it turned out that RCT pathway needs revising and supplementing with other data. Plenty of reviews have dealt with the issue of LCAT and its atherogenic aspects (Glomset 1968 , Sodhi et al. 1980 , Dobiášová 1983 , Dobiášová and Frohlich 1999 , Jonas 2000 , Rousset et al. 2009 , Rader 2009 , Calabresi and Franceschini 2010 , Rousset et al. 2011 , Kunnen and Van Eck 2012 , Ng 2012 , Calabresi et al. 2012 , Levinson and Wagner 2015 , Ossoli et al. 2016 . Some authors have found a protective effect of LCAT in patients with coronary heart disease (Solajic-Božičević et al. 1991 , Solajic-Božičević et al. 1994 , Hovingh et al. 2005 , Sethi et al. 2010 . Others, and probably majority of them, reported the increase in atherogenic risk by increasing the activity of LCAT or cholesterol esterification rate (Dobiášová et al. 1991 , Takao et al. 2001 , Guerin et al. 2001 , Santos et al. 2003 , Frohlich and Dobiášová 2003 , Dullaart et al. 2008 , Dullart et al. 2010 , Hollebooom et al. 2010 , Khera et al. 2011 , Dobiášová et al. 2011 , Li et al. 2013 , Kim et al. 2014 .
Free cholesterol meets the LCAT on the way from peripheral cells to the intravascular space and is transformed into CEs which leave this space in two ways. However, a number of small variations on this way may change atherogenic/anti-atherogenic impact of LCAT. Recently Philips (2014) reviewed four pathways for exporting free cholesterol from macrophages to extracellular HDL. The passive processes include simple diffusion via the aqueous phase and facilitated diffusion mediated by scavenger receptor class B, type I (SR-BI). The data about FC diffusion via aqueous phase were complemented by Czarnecka and Yokoyama (1995) in an earlier report on the regulation of cellular cholesterol efflux. SR-BI has also a significant role in the transfer of CE into the catabolic process in the liver (Acton et al. 1996 , Hoekstra 2017 . The active pathways are mediated by membrane lipid translocases such as the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. As stated by Philips (2014), both transporters mediate efflux of cholesterol from cells, but the reaction mechanisms are different. ABCG1 leads to redistribution of FC from cell interior into the plasma membranes. When activated pool of plasma membrane is created, it leads to the flux of cholesterol mass out of the cell by aqueous diffusion pathway, but not to lipid-free apoA. In contrast, the ABCA1 activity in the plasma membrane promotes efflux of phospholipids (with a preference of lecithin) and FC to lipid-free apoAI (plasma pre-β1/HDL).
When free cholesterol enters the intravascular space, it encounters the LCAT. As a relative small soluble glycoprotein (cca 67 kDa) LCAT operates in an aqueous plasma medium with less or more hydrophobic components. Therefore, the effectiveness of LCAT and cholesterol esterification rate will depend on many factors such as physicochemical nature of cholesterol-phospholipid bilayer (Yokoyama et al. 1980 , Parks et al. 2000 , the characteristics of the fatty acyls of lecithin, activator and inhibitor proteins -apoAI and apoAII (Fielding et al. 1972 ), apoC (Soutar et al. 1975 , specific cholesterol ATP-binding cassette transporters ABCA1 and ABCG1 (Philips 2014) and the size of lipoproteins.
The size of HDL, LDL and VLDL particles and activity of LCAT probably represent the strongest connection with atherogenic plasma profile. The associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis were found already in the eighties (Miller 1987) . Barter et al. (1984 Barter et al. ( , 1985 studied esterification of cholesterol by LCAT in two HDL subfractions, HDL-subfraction 3 (HDL3) and HDL-subfraction 2 (HDL2) and found that the two HDL subfractions may compete for interactions with the enzyme. HDL3 subfraction was highly effective substrate, while HDL2 subfraction function as an inhibitor of the cholesterol esterification reaction. Newer method of gradient gel electrophoresis in various gels (Nichols et al. 1986 , Williams et al. 1990 ) enabled split subfractions HDL2 and HDL3 into smaller subpopulations, which confirmed that the smallest particles HDL 3b,c are preferred substrate for LCAT, while the larger HDL 2b inhibit the reaction (Dobiášová et al. 1991 , Dobiášová et al. 1992 . The development of new methods has allowed to discover atherogenic potential of individual HDL subpopulations. The initial dichotomy of HDL2 and HDL3 did not bring unambiguous view relative to the CVD, while the NMR spectroscopy is able to do it (Freedman et al. 1998 , Jeyarajah et al. 2006 , Movva and Rader 2008 , Dobiášová et al. 2011 , Hafiane and Genest 2015 . These specific techniques confirmed that the best substrate for LCAT are only small HDL (HDL 3bc ) particles from the whole population of HDL3. The HDL small particles are substantially correlated with the cardiovascular risk, similarly as small dense LDL particles (Austin et al. 1988 ) and large VLDL particles. Large LDLs and particularly large HDL have shown reduced CVD risk.
Moreover, the removal of highly hydrophobic cholesteryl esters out of the intravascular space is also subjected to the regulation by lipoproteins of different size. In the first case the efflux of cholesteryl esters associated with the HDL2 and SR-BI is directed into liver and steroidogenic tissues (Acton et al. 1996 , Rigotti et al. 2003 . In the second case, CETP transfers cholesteryl esters to exchange for triglycerides in VLDL and then they go through the lipolytic cascade to LDL (Barter et al. 1982 , Guerin et al. 2001 . The functionality of LCAT is thus linked not only to HDL but it is also regulated by particle size of VLDL and LDL (Tani et al. 2016) . These two pathways differ in their impact on CVD risk: the HDL pathway into SR-BI is considered an anti-atherogenic because it aims to the catabolism in the liver, whereas the CETP pathway into VLDL appears to be atherogenic because it may share atherogenic VLDL-LDL fate.
The functionality of LCAT has been tested in many ways, which however did not avoid misunderstanding or technical errors in the methods. LCAT mass concentration and the activity of LCAT in a variety of substrates and the cholesterol esterification rate (CER) in the individual plasma samples were examined.
LCAT mass
The concentration of the LCAT has little effect on the rate of cholesterol esterification, being only 60 % (Albers et al. 1981) . Even at low LCAT concentrations, which are found in heterozygotes for LCAT deficiency, the ratio of CE to FC in plasma remains within the normal range (Ohta et al. 1995) . It was recently shown that LCAT mass correlates positively with HDL-cholesterol levels (HDLs are carriers of LCAT) and negatively with triglyceride levels in European individuals at high cardiovascular risk (Calabresi et al. 2011 ). This seemingly contradicts the fact that low LCAT does not represent an atherogenic risk, while low HDL and high triglycerides are the risk. A more likely explanation is simply that the mass of LCAT increases with the mass of HDL, which are the main carriers of plasma LCAT, but the resulting esterification is limited by the variability of HDL and LDL subpopulations.
LCAT activity
The purpose of determining the activity of LCAT is to establish the efficiency of autologous enzyme relative to the substrate which provides FC and which stimulates or limits its capacity. Many different substrates were used, such as liposomes, proteoliposomes (Vaisman and Remaley 2013) or plasma lipoproteins. The methods for measuring the activity of LCAT in vitro are focused on the direct measurement of a decrease of free cholesterol, on CE increase in a mixture of the enzyme and variety substrates, and on the fluorometric assay of LCAT phospholipase activity. The decrease of FC is measured by gas-liquid chromatography (Marcel and Vezina 1973) or by enzymatic methods (Patsch et al. 1976) . The determination of the activity LCAT as CE production is carried out in countless variations of radioassays with 3 H-cholesterol based upon the original publication of Stokke and Norum (1971) . However, in the recent years, fluorometric methods prevail (Parks et al. 2000 , Homan et al. 2013 ). The differences in LCAT activity in a variety of substrates can be enormous. For example, using DMPC (dimyristylphosphatidylcholine)-cholesterol liposomes as the substrate (Manabe et al. 1987) , LCAT activities in 120 human sera showed 4.4-to 5.4-fold higher values obtained by self-substrate radioassay method. Not only the specificity of different substrates determines values obtained but in radioassays it is essential how the radioactive label ( 3 H-cholesterol) is incorporated into the substrate (Dobiášová et al. 2000) . Perfect equilibration of the cholesterol label with lipoproteins is the method of "cold labeled substrate" Schützová 1986, Dobiášová and Frohlich 1996) which allows the transfer of radioactive label from the small filter paper disc into a solution of lipoprotein in the cold without the intervention of chemicals, heat or non-standard emulsion with albumin.
CER -cholesterol esterification rate and FER HDLfractional cholesterol esterification rate in apoB-lipoprotein depleted plasma
The problem of a method for the determination of cholesterol esterification rate (CER) is in the origin of free cholesterol that enters the LCAT reaction in the whole plasma. Since the esterification takes place mostly in HDL, a source of free cholesterol may be peripheral cells (including macrophages and foam cells), which are mostly not able to metabolize cholesterol. However, another source of free cholesterol for the esterification can be FC transported into HDL via aqueous diffusion from other lipoproteins. The paradox is that during the first five minutes of the process, only 5 % of cellular cholesterol is esterified in the pre-beta-3-HDL and alpha-HDL before it reaches LDL (Miida et al. 1990) . As the remainder of free cholesterol first reaches other lipoproteins containing apoB and then it comes freely transferred into HDL subpopulations that specifically regulate the rate of its esterification, it was concluded that practically all free cholesterol substrate for the LCAT procedure originates from LDL and VLDL particles (Huang et al. 1993) .
Plans for use of LCAT procedures in treatment of CVD
The measurement of LCAT mass, LCAT activity and LCAT esterification rate produced the hypothesis that by increasing the concentration of LCAT might be achieved a support of the RCT and the FC efflux from peripheral cells with resulting therapeutic effect in patients with atherosclerosis. However, this hypothesis in animal models has not proven. Over-expression of human LCAT in transgenic rabbits prevented diet-induced atherosclerosis (Hoeg et al. 1996 , Brousseau et al. 1997 . On the other hand, over-expression of human LCAT in mice did not prevent diet-induced atherosclerosis (Francone et al. 1997 , Mehlum et al. 1997 . On the contrary, high plasma HDL concentrations were associated with enhanced atherosclerosis in this animal model.
Not even 10 years later, large clinical trials found no protective effect of high concentration of HDL induced by the inhibition of cholesteryl ester transfer protein with torcetrapib (Nissen et al. 2007) . Neither the further studies with torcetrapib derivatives have brought a clinical benefit (Eyvazian and Frishman 2017). These experiences support the idea that a moderate changes in the process of transformation free cholesterol to cholesteryl esters may cause a butterfly effect by a change of the intended target.
FER HDL -fractional esterification rate in HDL
We have tried to compare LCAT esterification rate in normal population of men and women, in those with risks of cardiometabolic diseases and in those who already suffer of them. We studied that part of LCAT process (FER HDL ), which directly focuses on a change of free cholesterol into cholesteryl esters that takes place in HDL (Dobiášová and Frohlich 1996) It was shown that FER HDL is significantly elevated in humans at risk of atherosclerosis, e.g. higher in men than in women (those before menopause), higher in hypertensives and diabetics type 2 or in patients with positive findings on coronary angiography (Frohlich and Dobiášová 2003, Dobiášová et al. 2011) and those with risk factors of CVD (Rašlová et al. 2011) . Although FER HDL can predict the particle size in HDL and LDL, which, in turn, predicts CVD risk, it is not applicable to routine clinical examinations.
AIP -atherogenic index of plasma [log(TG/HDL-C)]
We looked for a clinically available marker that could at least partially replace the FER HDL test, which takes into account lipoprotein particle size distribution. Since Gaziano et al. (1997) reported that the ratio of triglycerides to HDL was a strong predictor of myocardial infarction, additional findings have been made regarding the relationship between HDL-C and TGs. Although an independent, inverse relationship between HDL-C and cardiovascular risk was demonstrated beyond any doubt (Miller 1987) , the contribution of triglycerides to cardiovascular risk was underestimated. However, triglycerides play a role in the regulation of lipoprotein interactions but they cannot serve convincingly as an independent marker of CVD. Among the first, who described the importance of linking triglycerides with HDL to predict CVD risk, was Treatment Panel III, referring this combination as an atherogenic dyslipidemia (Grundy et al. 2004) . This claim is supported by the evidence that an increased plasma concentration of TGs is associated with increased populations of small dense LDL and large VLDL, with elevated cholesteryl ester transfer from HDL to apoB containing lipoproteins (Guerin et al. 2001 ) and also with an increased incidence of coronary artery disease (Hokanson and Austin 1996) . Triglycerides have been proposed to be a major determinant of cholesterol esterification/transfer and HDL remodeling in human plasma (Murakami et al. 1995) .
Increased ratio TG/HDL-C thus represents a cardiometabolic risk which is determined mainly by the increase in risk subpopulations -large VLDL and small LDL and small HDL. Higher concentrations of total HDL cholesterol contain more cardioprotective HDL 2b subpopulation and large LDL (Jeyarajah et al. 2006) . For better expression of the relationship between triglycerides and HDL-C, we adopted the log-transformed molar ratio of TG/HDL-C, which we called atherogenic index of plasma (AIP). AIP is used as a logarithmically transformed value because in this form it produced better correlations and normal probability plots (Tan et al. 2004) and thus, it is more suitable from the statistical perspective than simple TG/HDL-C ratio (Urbina et al. 2011) . The correlation plot between simple TG/HDL-C ratio and HDL and LDL particle sizes is curvilinear, while with log-transformed TG/HDL-C ratio is linear (Dobiášová et al. 2011 ). We found that both tests -esterification rate in HDL (FER HDL ) as well as AIP -are controlled by the same size of the lipoproteins and highly correlate with each other (Fig. 1) . The significance of lipoprotein particle size for determining AIP is shown also by the respective correlation coefficients r (Table 1) (Dobiášová et al. 2011) . AIP correlates inversely with large HDLs and large LDL, which may be considered as anti-atherogenic effect, while AIP correlates positively with small dense LDLs and large VLDLs (atherogenic Vol. 66 effect). The values for both FER HDL and AIP increased significantly with increasing atherogenic risk (Dobiášová and Frohlich 2001 , Frohlich and Dobiášová 2003 , Rašlová et al. 2011 .
During the past years AIP was frequently used for the examination of different risk subjects (Dobiášová et al. 2001 , Di Castelnuovo et al. 2007 , Onat et al. 2010 , Soška et al. 2011 , Soška et al. 2012 , Stefanović et al. 2012 , Dos Santos-Weiss et al. 2013 , Onyedum et al. 2014 , Essiarab et al. 2014 , Hermans et al. 2012 , Akbas et al. 2014 , Vrablík et al. 2014 , Niroumand et al. 2015 , Zhu et al. 2015 , Nunes et al. 2015 , Shen et al. 2017 . When using readily available biochemical assays, AIP provides valuable information about the atherogenicity of plasma and may quantify the response to therapeutic intervention. The calculator of AIP, which sequesters investigated subjects into three categories of CVD risk (AIP Calculator on line), may be helpful in clinical practice.
Conclusions
The final atherogenic or antiatherogenic effects of LCAT depend on a balance between the efflux of free cholesterol from peripheral cells to the extracellular space, its esterification and destinations of CEs produced either into a futile excessive cycle together with apoB lipoproteins back to the plasma membranes or together with HDL 2b and SR-BI into the protective catabolism in the liver. Even if we comprehensively consider all LCAT activities when planning the therapy of cardiovascular diseases, it still remains a space for the butterfly effect when just a tiny deviation in a set of steps will change the sign of the impact. This does not detract from the importance of LCAT in maintaining the cholesterol metabolic balance and opens next possibilities for meaningful research. Biomarkers FER HDL and AIP can help to reveal the risk of CVD having in mind that it reflects not only the lipid concentrations but also the interaction of LCAT with tiny changes in lipoprotein subpopulations.
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